This study was supported by Grant-in-Aid for Scientific Research (17K14992 and 20K07612 to S. Kohno, and 17H03576, 17K19586, 19K22555, 20H03509, 26290037 to C. Takahashi), Research Grants of Princess Takamatsu Cancer Research Fund (23-255013), Promotion of Development of a Joint Usage/ Research System Project: Coalition of Universities for Research Excellence (CURE) Program (JPMXP1323015484) from MEXT, funding program for Next Generation World-Leading Researchers (LS049) from Cabinet Office of Japan, TaNeDS (C1010568), Astellas Foundation for Metabolic Disorder, Ono Medical Research Foundation, The Naito Foundation, Takeda Science Foundation, and Kieiotoyo Foundation.
Trending
- Pyruvate carboxylase drives therapeutic resistance to KRAS G12C inhibitors in KEAP1-mutant lung cancer
- Supercentenarians’ superpower to suppress cancer
- Making Outpatient Cellular Therapy Dosing the Default in Multiple Myeloma
- Bruce Haffty, MD, and Mutlay Sayan, MD, on Radiation Oncology’s Next Frontier and Mentorship
- FDA OKs Pirtobrutinib in Frontline CLL/SLL
- Assessing IMPT Outcomes Across Localized Prostate Cancer Risk Groups
- First-line ibrutinib-venetoclax in chronic lymphocytic leukemia: GLOW 67-month results and grade 3/4 adverse event-free progression-free survival
- Preoperative SBRT Shows High Resection Rates in Pancreatic Adenocarcinoma
Saturday, October 3
Pyruvate carboxylase drives therapeutic resistance to KRAS G12C inhibitors in KEAP1-mutant lung cancer
By NewsCancer
